Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Company Profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6770

Website: pliantrx.com

Address:

331 Oyster Point Boulevard, South San Francisco, United States

ka1954 Jul. 15 at 12:34 PM

$PLRX is this fucking going to stay dead forever? it seems like forever when i bought it

0 · Reply

Biotech_Pharma_Investor Jul. 14 at 3:38 PM

$PLRX PIPE for the integrin platform? (lots of PIPEs everywhere)

0 · Reply

nUme22 Jul. 10 at 2:51 PM

$TRAX money laundering scheme.. Seems way too many in BIO space.. $PLRX couple of yrs back. There are way too many like these Shorting wont work here till the weakness showed, there will be 50% drop suddenly..

0 · Reply

jackcoltrain Jul. 4 at 10:47 PM

$ENGN $PLRX I think better than holding cash in a savings account for this year

0 · Reply

Stef_DL Jun. 28 at 8:27 PM

$PLRX I have been wondering that myself. AI says: --- Pipeline Advancement: Progress and favorable safety/efficacy data from the ongoing FORTIFY trial, which is evaluating PLN-101095 in patients with immune-checkpoint-inhibitor (ICI)-refractory advanced or metastatic solid tumors. Strategic Partnerships & Buyouts: As a clinical-stage, pre-revenue company, securing a major pharmaceutical partnership or being acquired would immediately inject capital and validate their integrin-targeting technology platform. Macroeconomic Conditions & Sector Sentiment: Because Pliant is heavily reliant on future financing and trial outcomes, any easing of monetary policy (interest rate cuts) or a broader biotech sector rally would improve capital access and lift the stock. Investors remain cautious due to past trial discontinuations (such as the BEACON-IPF trial), but Pliant maintains enough capital to fund their operations and upcoming data readouts into the second half of 2028. So maybe a bit..?

0 · Reply

CapSampler Jun. 26 at 6:06 PM

$PLRX is there any hope here? Objectively, any potential point or solution for a comeback?

0 · Reply

ka1954 Jun. 25 at 10:36 PM

$PLRX when the fuck will this do something? its been more than a year its stuck

0 · Reply

focafoca99 Jun. 11 at 9:16 PM

$PLRX presented its 2026 annual meeting results, with shareholders electing three directors and ratifying its auditor.

0 · Reply

THSSKS Jun. 4 at 2:57 PM

$PLRX every time they present data, the stock goes down. They’re just going to burn it up. Bunch of greedy bod’s. They need to buy a better pipeline or stop this one asap and announce strategic alternatives

0 · Reply

clan Jun. 1 at 12:36 PM

$AZN ⚠️ Great news for diabetic kiddos ! ! ! 👍👍 FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 🚫💉 No needles! $CPIX $PLRX $GRI

0 · Reply

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

May 21, 2026, 5:29 PM EDT - 2 months ago

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 19, 2026, 11:30 AM EDT - 2 months ago

Pliant Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-11T20:57:49.000Z - 2 months ago

Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)

May 11, 2026, 4:05 PM EDT - 2 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 2 months ago

Pliant Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Pliant Therapeutics Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

2026-04-30T13:41:08.000Z - 2 months ago

Pliant Therapeutics doses first participant in FORTIFY expansion trial

$Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors$

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Pliant Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Pliant Therapeutics Proxy statement: Proxy filing

2026-04-19T17:00:49.000Z - 3 months ago

Pliant announces presentation of updated data from Phase 1 trial of PLN-101095

$Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting$

Apr 18, 2026, 1:31 PM EDT - 3 months ago

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

2026-03-30T22:05:10.000Z - 3 months ago

Pliant Therapeutics files $300M mixed securities shelf

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Pliant Therapeutics Registration statement: Registration filing

Mar 18, 2026, 9:00 AM EDT - 4 months ago

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

2026-03-13T11:10:14.000Z - 4 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Canaccord

2026-03-12T11:10:41.000Z - 4 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler

Mar 11, 2026, 5:00 PM EDT - 4 months ago

Pliant Therapeutics Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 4 months ago

Pliant Therapeutics Earnings release: Q4 2025

2026-03-11T20:27:59.000Z - 4 months ago

Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)

Mar 11, 2026, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Feb 25, 2026, 2:40 PM EST - 5 months ago

Pliant Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:00 AM EST - 5 months ago

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Dec 4, 2025, 12:30 PM EST - 8 months ago

Pliant Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 12:30 PM EST - 8 months ago

Pliant Therapeutics Slides: Piper Sandler 37th Annual Healthcare Conference

2025-12-04T12:35:15.000Z - 8 months ago

Pliant Therapeutics announces interim data from PLN-101095

$Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Dec 4, 2025, 7:30 AM EST - 8 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 1, 2025, 8:30 AM EST - 8 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

2025-11-06T23:45:29.000Z - 9 months ago

Pliant Therapeutics reports Q3 EPS (43c), consensus (52c)

Nov 6, 2025, 4:05 PM EST - 9 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:00 PM EST - 9 months ago

Pliant Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

Pliant Therapeutics Earnings release: Q3 2025

2025-10-10T09:05:07.000Z - 9 months ago

Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan

2025-08-10T18:10:14.000Z - 1 year ago

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

2025-08-08T11:16:07.000Z - 1 year ago

Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler

2025-08-07T21:40:19.000Z - 1 year ago

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Quarterly report: Q2 2025

Jun 27, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF

May 21, 2025, 4:03 PM EDT - 1 year ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

2025-05-08T21:45:41.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c)

2025-05-08T20:50:13.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)

May 8, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Quarterly report: Q1 2025

2025-05-01T21:00:50.000Z - 1 year ago

Pliant Therapeutics to reduce workforce by 45%

May 1, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

2025-03-17T12:10:07.000Z - 1 year ago

Pliant Therapeutics announces interim Phase 1 data from PLN-101095

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

2025-03-13T11:30:56.000Z - 1 year ago

Pliant Therapeutics adopts limited duration stockholder rights agreement

Mar 13, 2025, 7:20 AM EDT - 1 year ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Annual report: Q4 2024

Mar 3, 2025, 9:27 AM EST - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

ka1954 Jul. 15 at 12:34 PM

$PLRX is this fucking going to stay dead forever? it seems like forever when i bought it

0 · Reply

Biotech_Pharma_Investor Jul. 14 at 3:38 PM

$PLRX PIPE for the integrin platform? (lots of PIPEs everywhere)

0 · Reply

nUme22 Jul. 10 at 2:51 PM

0 · Reply

jackcoltrain Jul. 4 at 10:47 PM

$ENGN $PLRX I think better than holding cash in a savings account for this year

0 · Reply

Stef_DL Jun. 28 at 8:27 PM

0 · Reply

CapSampler Jun. 26 at 6:06 PM

$PLRX is there any hope here? Objectively, any potential point or solution for a comeback?

0 · Reply

ka1954 Jun. 25 at 10:36 PM

$PLRX when the fuck will this do something? its been more than a year its stuck

0 · Reply

focafoca99 Jun. 11 at 9:16 PM

$PLRX presented its 2026 annual meeting results, with shareholders electing three directors and ratifying its auditor.

0 · Reply

THSSKS Jun. 4 at 2:57 PM

0 · Reply

clan Jun. 1 at 12:36 PM

0 · Reply

GangsterX May. 28 at 7:24 PM

$PLRX hold and wait for news before September...

0 · Reply

djcal May. 24 at 4:12 PM

$PLRX $172.40M but subtract the debt load $28.78M leaves you $142.11M and just keeps getting smaller every quarter. Time and them doing nothing but collecting their huge salaries.

0 · Reply

ACInvestorBlog May. 22 at 1:39 PM

$PLRX on high alert for the coming sessions. Still under accumulation.

2 · Reply

ACInvestorBlog May. 21 at 3:53 PM

$PLRX There have been some big buy blocks popping up in the last few days. I reckon we’ll hear news anytime now. The whales are holding substantial positions here. On high alert. Institutional ownership overall: Around 82–97% of the float (high for a small-cap biotech), with roughly 120 institutions holding shares. Tang Capital is by far the largest holder and has been increasing its position.

0 · Reply

ACInvestorBlog May. 18 at 5:33 PM

$PLRX took some for a swing trade. Unusual buy block today. Company will participate in a fireside chat tomorrow at RBC Capital Markets Global Healthcare Conference.

1 · Reply

ACInvestorBlog May. 18 at 4:01 PM

$PLRX unusual block today and unusual tutes disclose last week 🤔

0 · Reply

StockTwitsGhost May. 15 at 4:44 PM

$PLRX $IRWD What do Ironwood Pharmaceuticals and Pliant Therapeutics have in common? Different science, different stories…same end result for shareholders: long-term shareholder destruction and underperformance, fading conviction, and charts that just won’t stop grinding lower. Different names, same question, what is the common theme? 📉🗑️

1 · Reply

focafoca99 May. 15 at 3:56 PM

$PLRX named its CEO Bernard Coulie as chair of Atisama board as the company advances its Phase 1 RB042 trial.

0 · Reply

GangsterX May. 14 at 4:11 PM

$PLRX Filled 1.17 Medium Size Thong ... this is a waiting game and it could take 4-6 months for it to Pop . I think they will acquire an asset. It cant sit like this forever with huge cash. Buy and Hold 4-6 months. I think Max 6 months.

0 · Reply

SQUEAKSBANDIT May. 13 at 8:01 PM

$PLRX i'd re-enter if i believed the board was willing to sell to tang, but i don't wanna take a two+ year journey while these guys draw salaries burn$ on the early stage assets and likely ask permission for a reverse (if they haven't already)

0 · Reply

THSSKS May. 13 at 2:01 PM

$PLRX this has a bad pipeline but I’ll rebuy between .90-$1 if it gets there. Bad pipeline and big ATM/ shelf might hold it back. I got a proxy to vote last week even though I sold last month but I’d vote no to anything they wanted. Just sell the company. Management gambling a couple hundred million on a phase 1 long shot

0 · Reply

SuperGreenToday May. 12 at 11:14 PM

$PLRX Share Price: $1.18 Contract Selected: Oct 16, 2026 $0.5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.28 – $0.34 Potential Upside: 54% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	69.35M
Revenue (ttm)	0.00
Net Income (ttm)	-149.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	532,600
Avg Vol	538,620
Day's Range	N/A - N/A
Shares Out	61.92M
Stochastic %K	30%
Beta	1.21
Analysts	Hold
Price Target	$2.50